Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,628 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In The Mix Clear all
Completed Phase 2 Interventional Results available

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00027560
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
alemtuzumab, cyclosporine, fludarabine phosphate, melphalan, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 29, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome

NCT02544152
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Huntsville, Alabama • North Little Rock, Arkansas • Chula Vista, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 29, 2026, 9:32 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Cannabis' Impact on Alcohol Consumption

NCT05389930
View directory record Official record
Conditions
Alcohol Drinking, Cannabis Use, Cannabis, Alcohol Use Disorder
Interventions
THC-dominant cannabis, CBD-dominant cannabis, Cannabis placebo, Alcohol, Alcohol placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years to 50 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 29, 2026, 9:32 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00507065
View directory record Official record
Conditions
ADHD
Interventions
Mixed salts of a single-entity amphetamine (ADDERALL XR), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 29, 2026, 9:32 AM EDT
Recruiting No phase listed Observational

Alcohol After Bariatric Surgery 2

NCT06257771
View directory record Official record
Conditions
Sleeve Gastrectomy
Interventions
Alcohol (Ethanol)
Drug
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 64 Years
Enrollment
88 participants
Timeline
2024 – 2028
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 9:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy

NCT04113382
View directory record Official record
Conditions
Bowel Preparation
Interventions
CLENPIQ, MIRALAX, SENNA
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
12 Months to 8 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Mobile, Alabama • San Diego, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 29, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Precision High-Intensity Training Through Epigenetics (PHITE)

NCT03380923
View directory record Official record
Conditions
Healthy
Interventions
Moderate Intensity, High Intensity
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 27 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 29, 2026, 9:32 AM EDT
Not listed Early Phase 1 Interventional

Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation

NCT03292445
View directory record Official record
Conditions
Immune Tolerance
Interventions
Immune tolerance after kidney transplant, Donor blood stem cells and T cells
Procedure · Drug
Lead sponsor
Samuel Strober
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Palo Alto, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 29, 2026, 9:32 AM EDT
Completed Not applicable Interventional

Reducing Depression Self-stigma and Increasing Treatment Seeking Intentions Among Youth

NCT06172075
View directory record Official record
Conditions
Stigma, Social, Mental Health Disorder, Depression
Interventions
Brief video intervention (Black Woman), Brief video intervention (Latinx Woman), Brief video intervention (White Woman), Vignette Control
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 25 Years
Enrollment
1,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 29, 2026, 9:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT04077723
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Englumafusp alfa, Obinutuzumab, Glofitamab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
4
States / cities
Pasadena, California • San Francisco, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 29, 2026, 9:32 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Rigorous Evaluation of the READY to Stand Curriculum to Prevent the Commercial Sexual Exploitation of Children

NCT06587529
View directory record Official record
Conditions
Sex Trafficking, Sex Crimes, Commercial Sex, Sexual Violence, Child Abuse, Sexual, Sex Offense
Interventions
The Set Me Free Project's (SMFP) READY to Stand (RTS)© Curriculum
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 19 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 29, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

NCT05760313
View directory record Official record
Conditions
Functional Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Months to 23 Months
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 29, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Clostridium Histolyticum Collagenase Injection for Urethral Disease

NCT02948842
View directory record Official record
Conditions
Urethral Stricture
Interventions
Clostridium Histolyticum Collagenase, Saline
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 29, 2026, 9:32 AM EDT
Terminated Phase 4 Interventional Results available

Allopurinol Maintenance Study for Bipolar Disorder

NCT00732251
View directory record Official record
Conditions
Bipolar Disorder, Mania, Mixed Mania
Interventions
Allopurinol
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 29, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma

NCT00401024
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
imatinib mesylate, pharmacological study, conventional surgery
Drug · Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 29, 2026, 9:32 AM EDT
Recruiting Phase 2Phase 3 Interventional

Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients

NCT07221370
View directory record Official record
Conditions
Clostridium Difficile Infection, Vancomycin Resistant Enterococci Infection
Interventions
Vancomycin 125mg, Placebo
Drug
Lead sponsor
Riverside University Health System Medical Center
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Moreno Valley, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 29, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)

NCT01070394
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
LDX Treatment
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 29, 2026, 9:32 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

NCT03792841
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Interventions
acapatamab, Pembrolizumab, Etanercept, Cytochrome P450 (CYP) Cocktail
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
13
States / cities
Campbell, California • Duarte, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 29, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers

NCT03411122
View directory record Official record
Conditions
Drug-drug Interactions
Interventions
napabucasin, cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 29, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia

NCT04877366
View directory record Official record
Conditions
Dietary Supplement
Interventions
Dietary Supplement: Sprinkled Format REDUCOSE., Reference control, Active comparator
Dietary Supplement · Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 29, 2026, 9:32 AM EDT
Completed Phase 4 Interventional

Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder

NCT00034580
View directory record Official record
Conditions
Bipolar Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
21
States / cities
Berkley, California • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 29, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers

NCT02304185
View directory record Official record
Conditions
Healthy
Interventions
gp140, 50 mcg, gp140, 50 mcg + Adjuvant, gp140, 250 mcg, gp140, 250 mcg + Adjuvant, Placebo
Biological · Drug
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 29, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Potato Consumption and Energy Balance

NCT03518515
View directory record Official record
Conditions
Obesity
Interventions
White potato (french fries), White potato (French fries), +seasoning, Almond
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 50 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 29, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma

NCT00002625
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer, Lymphoma
Interventions
topotecan hydrochloride, low-LET electron therapy, low-LET photon therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 29, 2026, 9:32 AM EDT